Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018.

Jorquera PA, Mishin VP, Chesnokov A, Nguyen HT, Mann B, Garten R, Barnes J, Hodges E, De La Cruz J, Xu X, Katz J, Wentworth DE, Gubareva LV.

Sci Rep. 2019 Feb 25;9(1):2676. doi: 10.1038/s41598-019-39276-1.

2.

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.

Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, Spencer S, Campbell AP, Sinner M, Reid H, Garten R, Katz JM, Fry AM, Barnes J, Wentworth DE.

Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.

3.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.

Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A.

Antiviral Res. 2018 Sep;157:38-46. doi: 10.1016/j.antiviral.2018.07.001. Epub 2018 Jul 3.

4.

The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.

Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, Truscon R, Eichelberger MC, Gubareva LV, Fry AM, Monto AS.

Clin Infect Dis. 2017 Oct 30;65(10):1644-1651. doi: 10.1093/cid/cix608.

5.

Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.

Gubareva LV, Sleeman K, Guo Z, Yang H, Hodges E, Davis CT, Baranovich T, Stevens J.

J Infect Dis. 2017 Sep 15;216(suppl_4):S566-S574. doi: 10.1093/infdis/jiw625.

PMID:
28934455
6.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.

Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.

7.

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART.

Gubareva LV, Fallows E, Mishin VP, Hodges E, Brooks A, Barnes J, Fry AM, Kramp W, Shively R, Wentworth DE, Weidemaier K, Jacobson R.

Euro Surveill. 2017 May 4;22(18). pii: 30529. doi: 10.2807/1560-7917.ES.2017.22.18.30529.

8.

Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.

Baranovich T, Vongphrachanh P, Ketmayoon P, Sisouk T, Chomlasack K, Khanthamaly V, Nguyen HT, Mishin VP, Marjuki H, Barnes JR, Garten RJ, Stevens J, Wentworth DE, Gubareva LV.

Emerg Infect Dis. 2017 Apr;23(4):686-690. doi: 10.3201/eid2304.161876.

9.

Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.

Solano MI, Woolfitt AR, Williams TL, Pierce CL, Gubareva LV, Mishin V, Barr JR.

Anal Chem. 2017 Mar 7;89(5):3130-3137. doi: 10.1021/acs.analchem.6b04902. Epub 2017 Feb 21.

10.

A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants.

Mishin VP, Baranovich T, Garten R, Chesnokov A, Abd Elal AI, Adamczyk M, LaPlante J, St George K, Fry AM, Barnes J, Chester SC, Xu X, Katz JM, Wentworth DE, Gubareva LV.

J Clin Microbiol. 2016 Dec 28;55(1):145-154. doi: 10.1128/JCM.01840-16. Print 2017 Jan.

11.

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.

Marjuki H, Mishin VP, Chai N, Tan MW, Newton EM, Tegeris J, Erlandson K, Willis M, Jones J, Davis T, Stevens J, Gubareva LV.

J Virol. 2016 Nov 14;90(23):10446-10458. doi: 10.1128/JVI.01284-16. Print 2016 Dec 1.

12.

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM.

J Infect Dis. 2016 Oct 1;214(7):1010-9. doi: 10.1093/infdis/jiw181. Epub 2016 May 6. Erratum in: J Infect Dis. 2017 Jun 1;215(11):1774.

13.

Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses.

Yang H, Carney PJ, Mishin VP, Guo Z, Chang JC, Wentworth DE, Gubareva LV, Stevens J.

J Virol. 2016 May 27;90(12):5770-5784. doi: 10.1128/JVI.00180-16. Print 2016 Jun 15.

14.

Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.

Okomo-Adhiambo M, Mishin VP, Sleeman K, Saguar E, Guevara H, Reisdorf E, Griesser RH, Spackman KJ, Mendenhall M, Carlos MP, Healey B, St George K, Laplante J, Aden T, Chester S, Xu X, Gubareva LV.

Antiviral Res. 2016 Apr;128:28-35. doi: 10.1016/j.antiviral.2016.01.009. Epub 2016 Jan 22.

PMID:
26808479
15.

Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013.

Thor SW, Nguyen H, Balish A, Hoang AN, Gustin KM, Nhung PT, Jones J, Thu NN, Davis W, Ngoc TN, Jang Y, Sleeman K, Villanueva J, Kile J, Gubareva LV, Lindstrom S, Tumpey TM, Davis CT, Long NT.

PLoS One. 2015 Aug 5;10(8):e0133867. doi: 10.1371/journal.pone.0133867. eCollection 2015.

16.

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV.

J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.

PMID:
25943200
17.

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV.

J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4.

18.

Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.

Tamura D, Okomo-Adhiambo M, Mishin VP, Guo Z, Xu X, Villanueva J, Fry AM, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2015 Apr;59(4):2374-9. doi: 10.1128/AAC.04939-14. Epub 2015 Feb 2.

19.

Structural and functional analysis of surface proteins from an A(H3N8) influenza virus isolated from New England harbor seals.

Yang H, Nguyen HT, Carney PJ, Guo Z, Chang JC, Jones J, Davis CT, Villanueva JM, Gubareva LV, Stevens J.

J Virol. 2015 Mar;89(5):2801-12. doi: 10.1128/JVI.02723-14. Epub 2014 Dec 24.

20.

Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14.

Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, Hand J, Garten RJ, Barnes J, Xiyan X, Villanueva JM, Gubareva LV; 2013–14 US Influenza Antiviral Working Group.

Emerg Infect Dis. 2015 Jan;21(1):136-41. doi: 10.3201/eid2101.141006.

21.

Use of highly pathogenic avian influenza A(H5N1) gain-of-function studies for molecular-based surveillance and pandemic preparedness.

Davis CT, Chen LM, Pappas C, Stevens J, Tumpey TM, Gubareva LV, Katz JM, Villanueva JM, Donis RO, Cox NJ.

MBio. 2014 Dec 12;5(6). pii: e02431-14. doi: 10.1128/mBio.02431-14. No abstract available.

22.

Advancing treatment options for influenza: challenges with the human influenza challenge.

Fry AM, Zhong W, Gubareva LV.

J Infect Dis. 2015 Apr 1;211(7):1033-5. doi: 10.1093/infdis/jiu543. Epub 2014 Oct 3. No abstract available.

PMID:
25281756
23.

Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Marjuki H, Mishin VP, Chesnokov AP, Jones J, De La Cruz JA, Sleeman K, Tamura D, Nguyen HT, Wu HS, Chang FY, Liu MT, Fry AM, Cox NJ, Villanueva JM, Davis CT, Gubareva LV.

J Infect Dis. 2015 Jan 15;211(2):249-57. doi: 10.1093/infdis/jiu447. Epub 2014 Aug 14.

PMID:
25124927
24.

Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.

Lu X, Liu F, Zeng H, Sheu T, Achenbach JE, Veguilla V, Gubareva LV, Garten R, Smith C, Yang H, Stevens J, Xu X, Katz JM, Tumpey TM.

Virology. 2014 Apr;454-455:169-75. doi: 10.1016/j.virol.2014.02.011. Epub 2014 Mar 5.

25.

An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Fry AM, Villanueva J, Gubareva LV.

J Infect Dis. 2014 Aug 1;210(3):435-40. doi: 10.1093/infdis/jiu105. Epub 2014 Feb 25.

26.

Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.

Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2014;58(4):2045-51. doi: 10.1128/AAC.02556-13. Epub 2014 Jan 21.

27.

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV.

Influenza Other Respir Viruses. 2014 Mar;8(2):258-65. doi: 10.1111/irv.12215. Epub 2013 Dec 2.

28.

Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.

Nguyen HT, Nguyen T, Mishin VP, Sleeman K, Balish A, Jones J, Creanga A, Marjuki H, Uyeki TM, Nguyen DH, Nguyen DT, Do HT, Klimov AI, Davis CT, Gubareva LV.

Emerg Infect Dis. 2013 Dec;19(12):1963-71. doi: 10.3201/eid1912.130705.

29.

The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.

Mishin VP, Sleeman K, Levine M, Carney PJ, Stevens J, Gubareva LV.

Antiviral Res. 2014 Jan;101:93-6. doi: 10.1016/j.antiviral.2013.11.001. Epub 2013 Nov 14.

PMID:
24239666
30.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

31.

R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV.

Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.

32.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, Xu X, Gubareva LV.

Antimicrob Agents Chemother. 2013 Nov;57(11):5209-15. doi: 10.1128/AAC.01086-13. Epub 2013 Aug 5.

33.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.

34.

Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.

Okomo-Adhiambo M, Sheu TG, Gubareva LV.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:44-9. doi: 10.1111/irv.12051. Review.

35.

Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.

Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y.

Antiviral Res. 2013 Mar;97(3):240-4. doi: 10.1016/j.antiviral.2012.12.013. Epub 2012 Dec 23.

PMID:
23267831
36.

Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient.

Shetty AK, Ross GA, Pranikoff T, Gubareva LV, Sechrist C, Guirand DM, Abramson J, Lin JJ.

Pediatr Transplant. 2012 Aug;16(5):E153-7. doi: 10.1111/j.1399-3046.2011.01489.x. Epub 2011 Mar 9.

PMID:
22764830
37.

Monitoring seasonal influenza A evolution: rapid 2009 pandemic H1N1 surveillance with an reverse transcription-polymerase chain reaction/electro-spray ionization mass spectrometry assay.

Jeng K, Massire C, Zembower TR, Deyde VM, Gubareva LV, Hsieh YH, Rothman RE, Sampath R, Penugonda S, Metzgar D, Blyn LB, Hardick J, Gaydos CA.

J Clin Virol. 2012 Aug;54(4):332-6. doi: 10.1016/j.jcv.2012.05.002. Epub 2012 Jun 4.

38.

Understanding influenza virus resistance to antiviral agents; early warning signs for wider community circulation.

Fry AM, Gubareva LV.

J Infect Dis. 2012 Jul 15;206(2):145-7. doi: 10.1093/infdis/jis338. Epub 2012 May 4. No abstract available.

PMID:
22561368
39.

The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.

Hurt AC, Okomo-Adhiambo M, Gubareva LV.

Methods Mol Biol. 2012;865:115-25. doi: 10.1007/978-1-61779-621-0_7.

PMID:
22528156
40.

The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.

Okomo-Adhiambo M, Hurt AC, Gubareva LV.

Methods Mol Biol. 2012;865:95-113. doi: 10.1007/978-1-61779-621-0_6.

PMID:
22528155
41.

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.

De Marco D, Clementi N, Mancini N, Solforosi L, Moreno GJ, Sun X, Tumpey TM, Gubareva LV, Mishin V, Clementi M, Burioni R.

PLoS One. 2012;7(4):e34415. doi: 10.1371/journal.pone.0034415. Epub 2012 Apr 4.

42.

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.

Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV.

Antiviral Res. 2012 Mar;93(3):381-6. doi: 10.1016/j.antiviral.2012.01.006. Epub 2012 Feb 7.

PMID:
22330888
43.

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

Nguyen HT, Fry AM, Gubareva LV.

Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3. Review.

PMID:
22311680
44.

Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.

Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM; US Antiviral Resistance Surveillance Working Group.

Emerg Infect Dis. 2012 Feb;18(2):308-11. doi: 10.3201/eid1802.111466.

45.

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.

Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals.

Lancet Infect Dis. 2012 Mar;12(3):240-8. doi: 10.1016/S1473-3099(11)70318-8. Epub 2011 Dec 18. Review.

PMID:
22186145
46.

A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.

Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, Mishin V, Di Pietro A, Vicenzi E, Siccardi AG, Clementi M, Burioni R.

PLoS One. 2011;6(12):e28001. doi: 10.1371/journal.pone.0028001. Epub 2011 Dec 5.

47.

Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.

Belser JA, Sleeman K, Pearce MB, Katz JM, Gubareva LV, Tumpey TM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1616-8. doi: 10.1128/AAC.06101-11. Epub 2011 Dec 12.

48.

Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial.

Dharan NJ, Fry AM, Kieke BA, Coleman L, Meece J, Vandermause M, Gubareva LV, Klimov AI, Belongia EA.

Influenza Other Respir Viruses. 2012 May;6(3):153-8. doi: 10.1111/j.1750-2659.2011.00312.x. Epub 2011 Nov 26.

49.

Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.

Sleeman K, Sheu TG, Moore Z, Kilpatrick S, Garg S, Fry AM, Gubareva LV.

Emerg Infect Dis. 2011 Nov;17(11):2043-6. doi: 10.3201/eid1711.110787.

50.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

Supplemental Content

Loading ...
Support Center